{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:51:59Z","timestamp":1771678319768,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinical-colorectal-cancer.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clcc.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T02:03:03Z","timestamp":1709949783000},"page":"174-182.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program"],"prefix":"10.1016","volume":"23","author":[{"given":"Daisuke","family":"Kotani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Izawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Ushida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Oizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clcc.2024.02.002_bib0001","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/bjc.2011.19","article-title":"BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer","volume":"104","author":"Yokota","year":"2011","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2024.02.002_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1276-z","article-title":"A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer","volume":"15","author":"Kawazoe","year":"2015","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.clcc.2024.02.002_bib0003","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/ijc.25555","article-title":"Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation","volume":"128","author":"Tie","year":"2011","journal-title":"Int J Cancer"},{"issue":"6","key":"10.1016\/j.clcc.2024.02.002_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131046","article-title":"High BRAF mutation frequency and marked survival differences in subgroups according to KRAS\/BRAF mutation status and tumor tissue availability in a prospective population-based metastatic colorectal cancer cohort","volume":"10","author":"Sorbye","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.clcc.2024.02.002_bib0005","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clcc.2024.02.002_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF-mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.clcc.2024.02.002_bib0007","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clcc.2024.02.002_bib0008","article-title":"Encorafenib (ENCO), binimetinib (BINI), and cetuximab (CETUX) in BRAF V600E-mutant metastatic colorectal cancer (BEACON CRC): including results of Japanese subset","author":"Yoshino","year":"2020"},{"key":"10.1016\/j.clcc.2024.02.002_bib0009","series-title":"JSCCR 2022 guidelines for the treatment of colorectal cancer","year":"2022"},{"issue":"4","key":"10.1016\/j.clcc.2024.02.002_bib0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"46","key":"10.1016\/j.clcc.2024.02.002_bib0011","doi-asserted-by":"crossref","first-page":"75013","DOI":"10.18632\/oncotarget.12601","article-title":"Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer","volume":"7","author":"Thomsen","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clcc.2024.02.002_bib0012","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V","article-title":"Peritoneal carcinomatosis in nongynecolagic malignancy a prospective study of prognostic factors","volume":"63","author":"Chu","year":"1989","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2024.02.002_bib0013","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cam4.2673","article-title":"Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.clcc.2024.02.002_bib0014","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/cts.13260","article-title":"Prognostic impact of pleural effusion in patients with malignancy: a systematic review and meta-analysis","volume":"15","author":"Yang","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"6","key":"10.1016\/j.clcc.2024.02.002_bib0015","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","article-title":"Effect of inhibition of the FGFR\u2013MAPK signaling pathway on the development of ocular toxicities","volume":"39","author":"Van der Noll","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"26","key":"10.1016\/j.clcc.2024.02.002_bib0016","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2011.41.5851","article-title":"Ocular toxicity of targeted therapies","volume":"30","author":"Renouf","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clcc.2024.02.002_bib0017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clcc.2024.02.002_bib0018","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10147-022-02264-z","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E\u2013mutated colorectal cancer: an early post-marketing phase vigilance study","volume":"28","author":"Sakata","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clcc.2024.02.002_bib0019","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/CAD.0000000000001106","article-title":"BRAF\/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells","volume":"32","author":"Sanagawa","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"25","key":"10.1016\/j.clcc.2024.02.002_bib0020","doi-asserted-by":"crossref","first-page":"e7196","DOI":"10.1097\/MD.0000000000007196","article-title":"Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report","volume":"96","author":"Maanaoui","year":"2017","journal-title":"Medicine (Baltimore)"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002824000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T12:52:53Z","timestamp":1717332773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002824000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1533002824000227"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2024.02.002","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}